Document Detail


Clinical results of drug eluting stents compared to bare metal stents for patients with ST elevation acute myocardial infarction.
MedLine Citation:
PMID:  18803074     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To investigate the clinical outcomes in patients with ST segment elevation acute myocardial infarction (STEMI) treated with drug eluting stents (DES) versus a matched control group of patients with STEMI treated with bare metal stents (BMS). METHODS: This registry included 122 patients with STEMI undergoing primary coronary angioplasty with DES implantation at our institution. The control group consisted of 506 patients implanted with BMS, who were matched for age, infarct location, and diabetic status. The incidences of major adverse cardiac events (MACE) including target vessel/lesion revascularization (TVR/TLR) and stent thrombosis were assessed up to 12 months. RESULTS: Twelve months follow up showed a non-significant trend towards reduced deaths (3.3% versus 7.1%, P=0.1), significantly reduced recurrent MI (0.0% versus 6.1%, P=0.02), TVR (5.7% versus 15.2%, P=0.006) and TLR (2.5% versus 14.0%, P=0.004) events in the DES group as compared to BMS group. The composite incidences of MACE at 12 months follow-up was lower in the DES group (11.5%) as compared to the BMS group (21.3%, P=0.01). CONCLUSION: According to our experiences, the use of DES in STEMI is safe and effective as compared to BMS. DES was effective in reducing the incidence of restenosis outcomes and overall adverse cardiac events up to 12 months.
Authors:
R Kornowski; H Vaknin-Assa; E Lev; I Ben-Dor; I Teplitsky; E Rechavia; D Brosh; S Fuchs; A Assali
Related Documents :
21232674 - Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progre...
11835634 - Angiographic outcome after intracoronary x-sizer helical atherectomy and thrombectomy: ...
16275124 - Role of adjunct pharmacologic therapy in the era of drug-eluting stents.
14766994 - Early experiences and clinical implications of drug-eluting stents: part 1.
14642154 - Advances in antithrombin therapy for st-elevation myocardial infarction.
17996824 - Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Acute cardiac care     Volume:  10     ISSN:  1748-2941     ISO Abbreviation:  Acute Card Care     Publication Date:  2008  
Date Detail:
Created Date:  2008-09-22     Completed Date:  2009-01-13     Revised Date:  2009-11-17    
Medline Journal Info:
Nlm Unique ID:  101276603     Medline TA:  Acute Card Care     Country:  Sweden    
Other Details:
Languages:  eng     Pagination:  167-72     Citation Subset:  IM    
Affiliation:
Cardiology Department, Rabin Medical Center, Petah-Tikva, The 'Sackler' Faculty of Medicine, Tel-Aviv University, Israel. rkornowski@clalit.org.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angioplasty, Transluminal, Percutaneous Coronary*
Drug-Eluting Stents*
Female
Humans
Immunosuppressive Agents / administration & dosage
Male
Middle Aged
Myocardial Infarction / therapy*
Paclitaxel / administration & dosage
Registries
Retrospective Studies
Sirolimus / administration & dosage,  analogs & derivatives
Stents*
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 0/zotarolimus; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Computer-based intervention with coaching: an example using the Incredible Years program.
Next Document:  Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidenc...